Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: Overview of therapeutic approaches

Folia Biologica

Volumn 52, Issue 4, 2006, Pages 119-136

  Klener Jr , P ^a   Andera L ^b   Klener, P ^a,c   Necas E ^a   Živný, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Akt; Apoptosis; Bcl 2 protein family; Bcr Abl; Cyclin dependent kinases (CD; Heat shock proteins (HSPs)Heat shock protein inhibitors (HSPI); Inhibitor of apoptosis proteins (IAPs); JAK; Leukaemia; Lymphoma; Mammalian target of rapamycin (mTOR); Mitogen activated protein kinase (MAPK)Phosphatidylinositol 3 kinase (P13K); NF B; Protein kinase B; Receptor tyrosine kinase; STAT; TNF related apoptosis inducing ligand

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APRIL PROTEIN; BAFF PROTEIN; DEATH RECEPTOR 4 ANTIBODY; DEATH RECEPTOR 5; DEATH RECEPTOR 5 ANTIBODY; FAS ANTIBODY; FAS LIGAND; FLICE INHIBITORY PROTEIN; GELDANAMYCIN; GEMTUZUMAB OZOGAMICIN; HEAT SHOCK PROTEIN; HERBIMYCIN A; INHIBITOR OF APOPTOSIS PROTEIN; MAPATUMOMAB; MONOCLONAL ANTIBODY; OBLIMERSEN; PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RITUXIMAB; SURVIVIN; TRITERPENOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL CLONE; CELL DEATH; CELL GROWTH; CLINICAL STUDY; CLINICAL TRIAL; DRUG APPROVAL; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

INTRACISTERNAL A-PARTICLES; MAMMALIA;

EID: 33750291707     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Review

References (209)

1. Alas, S., Emmanouilides, C., Bonavida, B. (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. 7, 709-723.
2. Alas, S., Bonavida, B. (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9, 316-326.
3. Alvi, A. J., Austen, B., Weston, V. J., Fegan, C., MacCallum, D., Gianella-Borradori, A., Lane, D. P., Hubank, M., Powell, J. E., Wei, W., Taylor, A. M., Moss, P. A., Stankovic, T. (2005) A novel CDK inhibitor, CYC2O2 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 105, 4484-4491.
4. Ambrosini, G., Adida, C., Altieri, D. C. (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921.
5. Ambrosini, G., Adida, C., Sirugo, G., Altieri, D. C. (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273, 11177-11182.
6. Aoki, Y., Feldman, G. M., Tosato, G. (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101, 1535-1542.
7. Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., Dimitrijevic, S., Mahon, F. X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N. C. P., Goldman, J. M. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347, 481-487.
8. Aron, J. L., Parthun, M. R., Marcucci, G., Kitada, S., Mone, A. P., Davis, M. E., Shen, T., Murphy, T., Wickham, J., Kanakry, C., Lucas, D. M., Reed, J. C., Grever, M. R., Byrd, J. C. (2003) Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLiP protein. Blood 102, 652-658.
9. Arora, A., Scholar, E. M. (2005) Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315, 971-979.
10. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtney, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z., Schwall, R. H. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
11. Badros, A. Z., Goloubeva, O., Rapoport, A. P., Ratterree, B., Gahres, N., Meisenberg, B., Takebe, N., Heyman, M., Zwiebel, J., Streicher, H., Gocke, C. D., Tomic, D., Flaws, J. A., Zhang, B., Fenton, R. G. (2005) Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 23, 4089-4099.
12. Ballestrero, A., Nencioni, A., Boy, D., Rocco, I., Garuti, A., Mela, G. S., Van Parijs, L., Brossart, P., Wesselborg, S., Patrone, F. (2004) Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin. Cancer Res. 10, 1463-1470.
13. Barragan, M., Bellosillo, B., Campas, C., Colomer, D., Pons, G., Gil, J. (2002) Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 99, 2969-2976.
14. Battle, T. E., Frank, D. A. (2003) STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood 102, 3016-3024.
15. Belka, C., Schmid, B., Marini, P., Durand, E., Rudner, J., Faltin, H., Bamberg, M., Schulze-Osthoff, K., Budach, W. (2001) Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene 20, 2190-2196.
16. Benekli, M., Baer, M. R., Baumann, H., Wetzler, M. (2003) Signal transducer and activator of transcription proteins in leukemias. Blood 101, 2940-2954.
17. Bianco, R., Melisi, D., Ciardiello, F., Tortora, G. (2006) Key cancer cell signal transduction pathways as therapeutic targets. Eur. J. Cancer 42, 290-294.
18. Blagosklonny, M. V. (2002) Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 16, 455-462.
19. Blume-Jensen, P., Hunter, T. (2001) Oncogenic kinase signalling. Nature 411, 355-365.
20. Bruserud, O. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90, 579.
21. Bug, G., Ritter, M., Wassmann, B., Schoch, C., Heinzel, T., Schwarz, K., Romanski, A., Kramer, O. H., Kampfmann, M., Hoelzer, D., Neubauer, A., Ruthardt, M., Ottmann, O. G. (2005) Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia. Cancer 104, 2717-2725.
22. Buss, J. L., Neuzil, J., Gellert, N., Weber, C., Ponka, P. (2003) Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem. Pharmacol. 65, 161-172.
23. Buss, J. L., Greene, B. T., Turner, J., Torti, F. M., Torti, S. V. (2004) Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 4, 1623-1635.
24. Byrd, J. C., Marcucci, G., Parthun, M. R., Xiao, J. J., Klisovic, R. B., Moran, M., Lin, T. S., Liu, S., Sklenar, A. R., Davis, M. E., Lucas, D. M., Fischer, B., Shank, R., Tejaswi, S. L., Binkley, P., Wright, J., Chan, K. K., Greven, M. R. (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105, 959-967.
25. Campo, S., Serlupi-Crescenzi, O., Arseni, B., Rossi, S., Saggio, I., Salone, B., Cherubini, G., Carminati, P., De Santis, R. (2005) Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma. Cytokine 31, 368-374.
26. Carter, B. Z., Gronda, M., Wang, Z., Welsh, K., Pinilla, C., Andreeff, M., Schober, W. D., Nefzi, A., Pond, G. R., Mawji, I. A., Houghten, R. A., Ostresh, J., Brandwein, J., Minden, M. D., Schuh, A. C., Wells, R. A., Messner, H., Chun, K., Reed, J. C., Schimmer, A. D. (2005) Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells. Blood 105, 4043-4050.
27. Castro, J. E., Prada, C. E., Loria, O., Kamal, A., Chen, L., Burrows, F. J., Kipps, T. J. (2005) ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106, 2506-2512.
28. Chauhan, D., Li, G., Podar, K., Hideshima, T., Shringarpure, R., Catley, L., Mitsiades, C., Munshi, N., Tai, Y. T., Suh, N., Gribble, G. W., Honda, T., Schlossman, R., Richardson, P., Sporn, M. B., Anderson, K. C. (2004) The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 103, 3158-3166.
29. Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P., Anderson, K. C. (2005) Proteasome inhibitor therapy in multiple myeloma. Mol. Cancer Ther. 4, 686-692.
30. Chen, J., DeAngelo, D. J., Kutok, J. L., Williams, I. R., Lee, B. H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A., Galinsky, I., Huntly, B., Cohen, P. S., Meyer, T., Fabbro, D., Roesel, J., Banerji, L., Griffin, J. D., Xiao, S., Fletcher, J. A., Stone, R. M., Gilliland, D. G. (2004) PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc. Natl. Acad. Sci. USA 101, 14479-14484.
31. Chen, R., Keating, M. J., Gandhi, V., Plunkett, W. (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106, 2513-2519.
32. Chernov, M. V., Ramana, C. V., Adler, V. V., Stark, G. R. (1998) Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proc. Natl. Acad. Sci. USA 95, 2284-2289.
33. Chowdhury, S. A., Kishino, K., Satoh, R., Hashimoto, K., Kikuchi, H., Nishikawa, H., Shirataki, Y., Sakagami, H. (2005) Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res. 25, 2055-2063.
34. Claessens, Y. E., Bouscary, D., Dupont, J. M., Picard, F., Melle, J., Gisselbrecht, S., Lacombe, C., Dreyfus, F., Mayeux, P., Fontenay-Roupie, M. (2002) In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 99, 1594-1601.
35. Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., Cross, N. C. P., Tefferi, A., Malone, J., Alam, R., Schrier, S. L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S. E., Stone, R., Gilliland, D. G. (2003a) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214.
36. Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., Lee, B. H., Williams, I. R., Coutre, S. E., Stone, R. M., DeAngelo, D. J., Marynen, P., Manley, P. W., Meyer, T., Fabbro, D., Neuberg, D., Weisberg, E., Griffin, J. D., Gilliland, D. G. (2003b) PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 3, 459-469.
37. Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M., Kantarjian, H. (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101, 1692-1697.
38. Cory, A. H., Somerville, L., Cory, J. G. (2005) Blockage of cyclin cdk's, PKC and phosphoinositol 3-kinase pathways leads to augmentation of apoptosis in drug-resistant leukemia cells: evidence for interactive effects of flavopiridol, LY 294002, roscovitine, wortmannin and UCN-01. Anticancer Res. 25, 101-106.
39. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., Almahdi, N., Cowell, J. K., Morgan, G. (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a Scid-hu mouse model. Oncogene 9, 3049-3055.
40. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., Grant, S. (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 61, 5106-5115.
41. Dai, Y., Rahmani, M., Pei, X. Y., Khanna, P., Han, S. I., Mitchell, C., Dent, P., Grant, S. (2005) Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105, 1706-1716.
42. De Graaf, A. O., de Witte, T., Jansen, J. H. (2004) Inhibitor of apoptosis proteins: new therapeutic targets in hematological cancer? Leukemia 18, 1751-1759.
43. De Keersmaecker, K., Cools, J. (2006) Chronic myeloproliferative disorders: a tyrosine kinase tale. Leukemia 20, 200-205.
44. Deininger, M. W. N., Goldman, J. M., Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356.
45. Der Veen, A. H., ten Hagen, T. L., de Wilt, J. H., van Ijken, M. G., Eggermont, A. M. (2000) An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res. 20, 3467-3474.
46. Derenne, S., Monia, B., Dean, N. M., Taylor, J. K., Rapp, M. J., Harousseau, J. L., Bataille, R., Amiot, M. (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100, 194-199.
47. Dispenzieri, A., Gertz, M. A., Lacy, M. Q., Geyer, S. M., Fitch, T. R., Fenton, R. G., Fonseca, R., Isham, C. R., Ziesmer, S. C., Erlichman, C., Bible, K. C. (2006) Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic endpoints. Haematologica 91, 390-393.
48. Doggrell, S. A. (2005) BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia. Expert. Opin. Investig. Drugs 14, 89-91.
49. Drexler, H. G., Gignac, S. M., Jones, R. A., Scott, C. S., Pettit, G. R., Hoffbrand, A. V. (1989) Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 74, 1747-1757.
50. Dutton, A., O'Neil, J. D., Milner, A. E., Reynolds, G. M., Starczynski, J., Crocker, J., Young, L. S., Murray, P. G. (2004) Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc. Natl. Acad. Sci. USA 101, 6611-6616.
51. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C., Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367.
52. Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H. D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H., Dorken, B. (1999) Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Steinberg cells. Blood 94, 3129-3134.
53. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., Loughran, T. P., Jr. (2001) Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107, 351-362.
54. Escobar-Diaz, E., Lopez-Martin, E. M., Hernandez, d. C., Puig-Kroger, A., Soto-Cerrato, V., Montaner, B., Giralt, E., Garcia-Marco, J. A., Perez-Tomas, R., Garcia-Pardo, A. (2005) AT514, a cyclic depsipeptide from Serratia marcescens, induces apoptosis of B-chronic lymphocytic leukemia cells: interference with the Akt/NF-kappaB survival pathway. Leukemia 19, 572-579.
55. Findley, H. W., Zhou, M. (1999) The clinical significance of Fas expression in leukemia: questions and controversies. Leukemia 13, 147-149.
56. Flaherty, K. T., Stevenson, J. P., O'Dwyer, P. J. (2001) Antisense therapeutics: lessons from early clinical trials. Curr. Opin. Oncol. 13, 499-505.
57. Foster, F. M., Traer, C. J., Abraham, S. M., Fry, M. J. (2003) The phosphoinositide (PI) 3-kinase family. J. Cell. Sci. 116, 3037-3040.
58. Gatto, S., Scappini, B., Pham, L., Onida, F., Milella, M., Ball, G., Ricci, C., Divoky, V., Verstovsek, S., Kantarjian, H. M., Keating, M. J., Cortes-Franco, J. E., Beran, M. (2003) The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica 88, 853-863.
59. Gautschi, O., Tschopp, S., Olie, R. A., Leech, S. H., Simoes-Wust, A. P., Ziegler, A., Baumann, B., Odermatt, B., Hall, J., Stahel, R. A., Zangemeister-Wittke, U. (2001) Activity of a novel bcl-2/ bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. Natl. Cancer Inst. 93, 463-471.
60. Gavin, A. L., Ait-Azzouzene, D., Ware, C. F., Nemazee, D. (2003) δBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J. Biol. Chem. 278, 38220-38228.
61. Giles, F. J., Albitar, M. (2005) Mammalian target of rapamycin as a therapeutic target in leukemia. Curr. Mol. Med. 5, 653-661.
62. Gojo, I., Zhang, B., Fenton, R. G. (2002) The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 8, 3527-3538.
63. Goldman, J. M., Melo, J. V. (2003) Chronic myeloid leukemia - advances in biology and new approaches to treatment. N. Engl. J. Med. 349, 1451-1464.
64. Gorre, M. E., Ellwood-Yen, K., Chiosis, G., Rosen, N., Sawyers, C. L. (2002) BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 100, 3041-3044.
65. Greil, R., Anether, G., Johrer, K., Tinhofer, I. (2003) Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J. Leukoc. Biol. 74, 311-330.
66. Grullich, C., Richter, M., Exner, S., Finke, J. (2003) Fas ligand is not constitutively expressed in low-grade B-cell lymphoma and B-lymphoblastoid cells. Eur. J. Haematol. 71, 184-188.
67. Guo, F., Sigua, C., Bali, P., George, P., Fiskus, W., Scuto, A., Annavarapu, S., Mouttaki, A., Sondarva, G., Wei, S., Wu, J., Djeu, J., Bhalla, K. (2005) Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 105, 1246-1255.
68. Hahn, M., Li, W., Yu, C., Rahmani, M., Dent, P., Grant, S. (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways. Mol. Cancer Ther. 4, 457-470.
69. Hao, C., Song, J. H., Hsi, B., Lewis, J., Song, D. K., Petruk, K. C., Tyrrell, D. L., Kneteman, N. M. (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res. 64, 8502-8506.
70. Hazar, V., Berber, Z., Pestereli, E., Coskun, M., Yesilipek, A., Karpuzoglu, G., Yegin, O. (2005) Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Pediatr. Hematol. Oncol. 22, 247-256.
71. He, B., Chadburn, A., Jou, E., Schattner, E. J., Knowles, D. M., Cerutti, A. (2004) Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J. Immunol. 172, 3268-3279.
72. Henderson, S., Huen, D., Rowe, M., Dawson, C., Johnson, G., Rickinson, A. (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc. Natl. Acad. Sci. USA 90, 8479-8483.
73. sHockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., Korsmeyer, S. J. (1990) Bcl-2 is an inner mitochondrial-membrane protein that blocks programmed cell death. Nature 348, 334-336.
74. Holcik, M., Gibson, H., Korneluk, R. G. (2001) XIAP: apoptotic brake and promising therapeutic target. Apoptosis 6, 253-261.
75. Huang, Y., Lu, M., Wu, H. (2004) Antagonizing XIAP-mediated caspase-3 inhibition: Achilles' heel of cancers? Cancer Cell 5, 1-2.
76. Ikeda, T., Nakata, Y., Kimura, F., Sato, K., Anderson, K., Motoyoshi, K., Sporn, M., Kufe, D. (2004) Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol. Cancer Ther. 3, 39-45.
77. Inoue, S., MacFarlane, M., Harper, N., Wheat, L. M., Dyer, M. J., Cohen, G. M. (2004a) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death. Differ. 11, S193-S206.
78. Inoue, S., Snowden, R. T., Dyer, M. J., Cohen, G. M. (2004b) CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia 18, 948-952.
79. Ito, Y., Pandey, P., Place, A., Sporn, M. B., Gribble, G. W., Honda, T., Kharbanda, S., Kufe, D. (2000) The novel triterpenoid 2-cyano-3, 12-dioxoolean- 1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ. 11, 261-267.
80. James, C., Ugo, V., Le Couedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, J. L., Constantinescu, S. N., Casadevall, N., Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148.
81. Janus, A., Robak, T., Smolewski, P. (2005) The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumorigenesis and targeted antitumour therapy. Cell Mol. Biol. Lett. 10, 479-498.
82. Jia, W., Yu, C., Rahmani, M., Krystal, G., Sausville, E. A., Dent, P., Grant, S. (2003) Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 102, 1824-1832.
83. Jo, M., Kim, T. H., Seol, D. W., Esplen, J. E., Dorko, K., Billiar, T. R., Strom, S. C. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6, 564-567.
84. Kalinowski, D. S., Richardson, D. R. (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 547-583.
85. Karp, J. E., Passaniti, A., Gojo, I., Kaufmann, S., Bible, K., Garimella, T. S., Greer, J., Briel, J., Smith, B. D., Gore, S. D., Tidwell, M. L., Ross, D. D., Wright, J. J., Colevas, A. D., Bauer, K. S. (2005) Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin. Cancer Res. 11, 8403-8412.
86. Kelly, W. K., Richon, V. M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, M., Schwartz, L., Richardson, S., Rosa, E., Drobnjak, M., Cordon-Cordo, C., Chiao, J. H., Rifkind, R., Marks, P. A., Scher, H. (2003) Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9, 3578-3588.
87. Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., Richardson, S., Chu, E., Olgac, S., Marks, P. A., Scher, H., Richon, V. M. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23, 3923-3931.
88. Kennedy, S. G., Kandel, E. S., Cross, T. K., Hay, N. (1999) Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria. Mol. Cell. Biol. 19, 5800-5810.
89. Kern, C., Cornuel, J. F., Billard, C., Tang, R., Rouillard, D., Stenou, V., Defrance, T., Ajchenbaum-Cymbalista, F., Simonin, P. Y., Feldblum, S., Kolb, J. P. (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103, 679-688.
90. Kim, H. J., Hawke, N., Baldwin, A. S. (2006) NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 13, 738-747.
91. Kim, Y., Suh, N., Sporn, M., Reed, J. C. (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329.
92. Klener, P. Jr., Anděra, L., Klener, P., Nečas, E., Živný, J. (2006) Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of apoptotic pathways. Folia Biol. (Praha) 52, 34-44.
93. Klisovic, M. I., Maghraby, E. A., Parthun, M. R., Guimond, M., Sklenar, A. R., Whitman, S. P., Chan, K. K., Murphy, T., Anon, J., Archer, K. J., Rush, L. J., Plass, C., Grever, M. R., Byrd, J. C., Marcucci, G. (2003) Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia 17, 350-358.
94. Koivunen, J., Aaltonen, V., Peltonen, J. (2006) Protein kinase C (PKC) family in cancer progression. Cancer Lett. 235, 1-10.
95. Konopleva, M., Tsao, T., Ruvolo, P., Stiouf, I., Estrov, Z., Leysath, C. E., Zhao, S., Harris, D., Chang, S., Jackson, C. E., Munsell, M., Suh, N., Gribble, G., Honda, T., May, W. S., Sporn, M. B., Andreeff M. (2002) Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99, 326-335.
96. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790.
97. Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U., Gattermann, N. (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104, 1266-1269.
98. Kuendgen, A., Schmid, M., Schlenk, R., Knipp, S., Hildebrandt, B., Steidl, C., Germing, U., Haas, R., Dohner, H., Gattermann, N. (2006) The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119.
99. Kurzrock, R., Albitar, M., Cortes, J. E., Estey, E. H., Faderl, S. H., Garcia-Manero, G., Thomas, D. A., Giles, F. J., Ryback, M. E., Thibault, A., De Porre, P., Kantarjian, H. M. (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J. Clin. Oncol. 22, 1287-1292.
100. Kurzrock, R., Kantarjian, H. M., Druker, B. J., Talpaz, M. (2003) Philadelphia chromosome-positive leukemias: From basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138, 819-830.
101. Lacrima, K., Valentini, A., Lambertini, C., Taborelli, M., Rinaldi, A., Zucca, E., Catapano, C., Cavalli, F., Gianella-Borradori, A., MacCallum, D. E., Bertoni, F. (2005) In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann. Oncol. 16, 1169-1176.
102. Lancet, J. E., Karp, J. E. (2003) Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102, 3880-3889.
103. Le, N. T., Richardson, D. R. (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim. Biophys. Acta 1603, 31-46.
104. Lee, J. J., Chung, I. J., Park, M. R., Ryang, D. W., Park, C. S., Kim, H. J. (2001) Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leuk. Res. 25, 1067-1073.
105. Lee, M. R., Dominguez, C. (2005) MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38 alpha protein. Curr. Med. Chem. 12, 2979-2994.
106. Lee, Y. K., Isham, C. R., Kaufman, S. H., Bible, K. C. (2006) Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol. Cancer Ther. 5, 138-148.
107. Lepelley, P., Grardel, N., Erny, O., Iaru, T., Obein, V., Cosson, A., Fenaux, P. (1998) Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk. Lymphoma 30, 307-312.
108. Letai, A., Sorcinelli, M. D., Beard, C., Korsmeyer, S. J. (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6, 241-249.
109. Letai, A. (2005) Pharmacological manipulation of Bcl-2 family members to control cell death. J. Clin. Invest. 115, 2648-2655.
110. Levis, M., Allebach, J., Tse, K. F., Zheng, R., Baldwin, B. R., Smith, B. D., Jones-Bolin, S., Ruggeri, B., Dionne, C., Small, D. (2002) A FLT3 -targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99, 3885-3891.
111. Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H. G., Brucker, M. J., Buser, C. A., Davide, J. P., deSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M. S., Kral, A. M., Liu, D., Lumma, W. C., Machotka, S. V., Rands, E., Williams, T. M., Graham, S. L., Hartman, G. D., Oliff, A. I., Heimbrook, D. C., Kohl, N. E. (2001) Evaluation of farnesyl: protein transferase and geranylgeranyl: protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758-8768.
112. Locksley, R. M., Killeen, N., Lenardo, M. J. (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501.
113. Lovejoy, D. B., Richardson, P. R. (2003) Iron chelators as anti-neoplastic agents: Current developments and promise of the PIH class of chelators. Curr. Med. Chem. 10, 1035-1049.
114. Lu, T., Stark, G. R. (2004) Cytokine overexpression and constitutive NF kappa B in cancer. Cell Cycle 3, 1114-1117.
115. Ma, Y., Lakshmikanthan, V., Lewis, R. W., Kumar, M. V. (2006) Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol. Cancer Ther. 5, 170-178.
116. MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., Green, S. R. (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399-5407.
117. Mackay, F., Schneider, P., Rennert, P., Browning, J. (2003) BAFF and APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21, 231-264.
118. Marcucci, G., Byrd, J. C., Dai, G., Klisovic, M. I., Kourlas, P. J., Young, D. C., Cataland, S. R., Fisher, D. B., Lucas, D., Chan, K. K., Porcu, P., Lin, Z. P., Farag, S. F., Frankel, S. R., Zwiebel, J. A., Kraut, E. H., Balcerzak, S. P., Bloomfield, C. D., Grever, M. R., Caligiuri, M. A. (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101, 425-432.
119. Marcucci, G., Stock, W., Dai, G., Klisovic, R. B., Liu, S., Klisovic, M. I., Blum, W., Kefauver, C., Sher, D. A., Green, M., Moran, M., Maharry, K., Novick, S., Bloomfield, C. D., Zwiebel, J. A., Larson, R. A., Grever, M. R., Chan, K. K., Byrd, J. C. (2005) Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J. Clin. Oncol. 23, 3404-3411.
120. Marks, P., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., Kelly, W. K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202.
121. Mathas, S., Lietz, A., Anagnostopoulos, I., Hummel, F., Wiesner, B., Janz, M., Jundt, F., Hirsch, B., Jobrens-Leder, K., Vornlocher, H. P., Bommert, K., Stein, H., Dorken, B. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J. Exp. Med. 199, 1041-1052.
122. Mesa, R. A., Tefferi, A., Gray, L. A., Reeder, T., Schroeder, G., Kaufmann, S. H. (2003) In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 17, 849-855.
123. Milella, M., Precupanu, C. M., Gregorj, C., Riceiardi, M. R., Petrucci, M. T., Kornblau, S. M., Tafuri, A., Andreeff, M. (2005) Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr. Pharm. Des. 11, 2779-2795.
124. Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Kung, A. L., Davies, F. E., Morgan, G., Akiyama, M., Shringarpure, R., Munshi, N. C., Richardson, P. G., Hideshima, T., Chauhan, D., Gu, X., Bailey, C., Joseph, M., Libermann, T. A., Rosen, N. S., Anderson, K. C. (2006) Antimyeloma activity of heat shock protein-90 inhibition. Blood 107, 1092-1100.
125. Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Reme, T., Lugagne, C., Moine, P., Rossi, J. F., Klein, B., Tarte, K. (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103, 3148-3157.
126. Morrison, D. K., Davis, R. J. (2003) Regulation of map kinase signaling modules by scaffold proteins in mammals. Annu. Rev. Cell. Dev. Biol. 19, 91-118.
127. Nemunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R., Dorr, A., Von Hoff, D., Eckhardt, S. G. (1999) Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J. Clin. Oncol. 17, 3586-3595.
128. Nguyen, P. L., Harris, N. L., Ritz, J., Robertson, M. J. (1996) Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am. J. Pathol. 148, 847-853.
129. Nishikori, M., Maesako, Y., Ueda, C., Kurata, M., Uchiyama, T., Ohno, H. (2003) High-level expression of BCL3 differentiates t(2; 5)(p23; q35)-positive anaplastic large cell lymphoma from Hodgkin disease. Blood 101, 2789-2796.
130. Nishio, M., Endo, T., Tsukada, N., Ohata, J., Kitada, S., Reed, J. C., Zvaifler, N. J., Kipps, T. J. (2005) Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1α. Blood 106, 1012-1020.
131. O'Brien, S. M., Cunningham, C. C., Golenkov, A. K., Turkina, A. G., Novick, S. C., Rai, K. R. (2005) Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23, 7697-7702.
132. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., Nagata, S. (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809.
133. Ohshima, K., Haraoka, S., Sugihara, M., Suzumiya, J., Kawasaki, C., Kanda, M., Kikuchi, M. (2000) Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett. 160, 89-97.
134. Oudejans, J. J., van den Brule, A. J., Jiwa, N. M., de Bruin, P. C., Ossenkoppele, G. J., van, d., V., Walboomers, J. M., Meijer, C. J. (1995) BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 86, 1893-1902.
135. Pardanani, A., Tefferi, A. (2004) Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931-1939.
136. Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O'Reilly, L. A., Waterhouse, N. J., Trapani, J. A., Johnstone, R. W. (2003) Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. 63, 4460-4471.
137. Pei, X. Y., Dai, Y., Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. 10, 3839-3852.
138. Pene, F., Claessens, Y. E., Muller, O., Viguie, F., Mayeux, P., Dreyfus, F., Lacombe, C., Bouscary, D. (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21, 6587-6597.
139. Pham, L. V., Tamayo, A. T., Yoshimura, L. C., Lo, P., Ford, R. J. (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J. Immunol. 171, 88-95.
140. Plasilova, M., Zivny, J., Jelinek, J., Neuwirtova, R., Cermak, J., Necas, E., Andera, L., Stopka, T. (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16, 67-73.
141. Platanias, L. C. (2003) Map kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679.
142. Propper, D. J., McDonald, A. C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J. P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., Kaye, S. B., Ganesan, T. S., Talbot, D. C., Harris, A. L., Twelves, C. (2001) Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19, 1485-1492.
143. Raffoux, E., Chaibi, P., Dombret, H., Degos, L. (2005) Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia. Haematologica 90, 986-988.
144. Rahmani, M., Grant, S. (2002) UCN-01 (7-hydroxystaurosporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). Cell Cycle 1, 273-281.
145. Raje, N., Kumar, S., Hideshima, T., Roccaro, A., Ishitsuka, K., Yasui, H., Shiraishi, N., Chauhan, D., Munshi, N. C., Green, S. R., Anderson, K. C. (2005) Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106, 1042-1047.
146. Rao, P. H., Houldsworth, J., Dyomina, K., Parsa, N. Z., Cigudosa, J. C., Louie, D. C., Popplewell, L., Offit, K., Jhanwar, S. C., Chaganti, R. S. (1998) Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 92, 234-240.
147. Rao, S., Watkins, D., Cunningham, D., Dunlop, D., Johnson, P., Selby, P., Hancock, B. W., Fegan, C., Culligan, D., Schey, S., Morris, T. C., Lissitchkov, T., Oliver, J. W., Holmlund, J. T. (2004) Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. Ann. Oncol. 15, 1413-1418.
148. Ray, S., Lu, Y., Kaufmann, S. H., Gustafson, W. C., Karp, J. E., Boldogh, I., Fields, A. P., Brasier, A. R. (2004) Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis. J. Biol. Chem. 279, 35604-35615.
149. Recher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos, S. C., Mas, V. M., Benzaquen, D., Laurent, G., Huguet, F., Payrastre, B. (2005a) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105, 2527-2534.
150. Recher, C., Dos, S. C., Demur, C., Payrastre, B. (2005b) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4, 1540-1549.
151. Reed, J. C., Pellecchia, M. (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106, 408-418.
152. Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., Foa, R., Lo, C. F., Peschle, C., Testa, U. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica 90, 612-624.
153. Richardson, D. R. (2005) Molecular mechanisms of iron uptake by cells and the use of iron chelators for the treatment of cancer. Curr. Med. Chem. 12, 2711-2729.
154. Ringshausen, I., Schneller, F., Bogner, C., Hipp, S., Duyster, J., Peschel, C., Decker, T. (2002) Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ. Blood 100, 3741-3748.
155. Rosato, R. R., Dai, Y., Almenara, J. A., Maggio, S. C., Grant, S. (2004) Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 18, 1780-1788.
156. Satou, Y., Nosaka, K., Koya, Y., Yasunaga, J. I., Toyokuni, S., Matsuoka, M. (2004) Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18, 1357-1363.
157. Schepers, H., Geugien, M., van der, T. M., Bryantsev, A. L., Kampinga, H. H., Eggen, B. J., Vellenga, E. (2005) HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp. Hematol. 33, 660-670.
158. Schimmer, A. D. (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res. 64, 7183-7190.
159. Schimmer, A. D., Welsh, K., Pinilla, C., Wang, Z., Krajewska, M., Bonneau, M. J., Pedersen, I. M., Kitada, S., Scott, F. L., Bailly-Maitre, B., Glinsky, G., Scudiero, D., Sausville, E., Salvesen, G., Nefzi, A., Ostresh, J. M., Houghten, R. A., Reed, J. C. (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5, 25-35.
160. Schittenhelm, M. M., Shiraga, S., Schroeder, A., Corbin, A. S., Griffith, D., Lee, F. Y., Bokemeyer, C., Deininger, M. W., Druker, B. J., Heinrich, M. C. (2006) Dasatinib (BMS354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66, 473-481.
161. Schneider, P., Tschopp, J. (2003) BAFF and the regulation of B cell survival. Immunol. Lett. 88, 57-62.
162. Shain, K. H., Landowski, T. H., Dalton, W. S. (2002) Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168, 2544-2553.
163. Shao, Y., Gao, Z., Marks, P. A., Jiang, X. (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA 101, 18030-18035.
164. Shapiro, G. I. (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. 10, 4270s-4275s.
165. Shi, Y. (2004) Caspase activation, inhibition, and reactivation: a mechanistic view. Protein Sci. 13, 1979-1987.
166. Shipman, C. M., Croucher, P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916.
167. Shtivelman, E., Lifshitz, B., Gale, R. P., Canaani, E. (1985) Fused transcript of Abl and Bcr genes in chronic myelogenous leukemia. Nature 315, 550-554.
168. Siebenlist, U., Franzoso, G., Brown, K. (1994) Structure, regulation and function of NF-κB. Annu. Rev. Cell Biol. 10 405-455.
169. Siegmund, D., Hadwiger, P., Pfizenmaier, K., Vornlocher, H. P., Wajant, H. (2002) Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol. Med. 8, 725-732.
170. Skinnider, B. F., Elia, A. J., Gascoyne, R. D., Patterson, B., Trumper, L., Kapp, U., Mak, T. W. (2002) Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Steinberg cells of Hodgkin lymphoma. Blood 99, 618-626.
171. Skorski, T., Bellacosa, A., Nieborowska-Skorska, M., Majewski, M., Martinez, R., Choi, J. K., Trotta, R., Wlodarski, P., Perrotti, D., Chan, T. O., Wasik, M. A., Tsichlis, P. N., Calabretta, B. (1997) Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16, 6151-6161.
172. Soh, J. W., Weinstein, I. B. (2003) Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J. Biol. Chem. 278, 34709-34716.
173. Song, G., Ouyang, G., Bao, S. (2005) The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. 9, 59-71.
174. Spiekermann, K., Biethahn, S., Wilde, S., Hiddemann, W., Alves, F. (2001) Constitutive activation of STAT transcription factors in acute myelogenous leukemia. Eur. J. Haematol. 67, 63-71.
175. Stadheim, T. A., Suh, N., Ganju, N., Sporn, M. B., Eastman, A. (2002) The novel triterpenoid 2-cyano-3, 12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem. 277, 16448-16455.
176. Steinberg, S. F. (2004) Distinctive activation mechanisms and functions for protein kinase Cδ. Biochem. J. 384, 449-459.
177. Stone, R. M., DeAngelo, D. J., Klimek, V., Galinsky, I., Estey, E., Nimer, S. D., Grandin, W., Lebwohl, D., Wang, Y., Cohen, P., Fox, E. A., Neuberg, D., Clark, J., Gilliland, D. G., Griffin, J. D. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105, 54-60.
178. Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., Nagata, S. (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186, 2045-2050.
179. Suhara, T., Kim, H. S., Kirshenbaum, L. A., Walsh, K. (2002) Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol. Cell Biol. 22, 680-691.
180. Sutheesophon, K., Kobayashi, Y., Takatoku, M. A., Ozawa, K., Kano, Y., Ishii, H., Furukawa, Y. (2006) Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. 115, 78-90.
181. Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., Okumura, K. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169.
182. Tassone, P., Neri, P., Burger, R., Savino, R., Shammas, M., Catley, L., Podar, K., Chauhan, D., Masciari, S., Gozzini, A., Tagliaferri, P., Venuta, S., Munshi, N. C., Anderson, K. C. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma. Clin. Cancer Res. 11, 4251-4258.
183. Teachey, D. T., Obzut, D. A., Cooperman, J., Fang, J., Carroll, M., Choi, J. K., Houghton, P. J., Brown, V. I., Grupp, S. A. (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149-1155.
184. Thomas, R. K., Kallenborn, A., Wickenhauser, C., Schultze, J. L., Draube, A., Vockerodt, M., Re, D., Diehl, V., Wolf, J. (2002) Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 160, 1521-1528.
185. Thomas, X., Campos, L., Le, Q. H., Guyotat, D. (2005) Heat shock proteins and acute leukemias. Hematology 10, 225-235.
186. Tortora, G., Caputo, R., Damiano, V., Caputo, R., Troiani, T., Veneziani, B. M., De Placido, S., Bianco, A. R., Zangemeister-Wittke, U., Ciardiello, F. (2003) Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity. Clin. Cancer Res. 9, 866-871.
187. Travis, J. (2004) Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance. Science 305, 319-321.
188. Tucker, S. J., Rae, C., Littlejohn, A. F., Paul, A., MacEwan, D. J. (2004) Switching leukemia cell phenotype between life and death. Proc. Natl. Acad. Sci. USA 101, 12940-12945.
189. Ueda, Y., Hirai, S., Osada, S., Suzuki, A., Mizuno, K., Ohno, S. (1996) Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271, 23512-23519.
190. Unnithan, J., Macklis, R. M. (2004) TRAIL induction by radiation in lymphoma patients. Cancer Invest. 22, 522-525.
191. Valentino, L., Pierre, J. (2006) JAW/STAT signal transduction: Regulators and implication in hematological malignancies. Biochem. Pharmacol. 71, 713-721.
192. van de Donk, N. W., de Weerdt, O., Veth, G., Eurelings, M., van Stralen, E., Frankel, S. R., Hagenbeek, A., Bloem, A. C., Lokhorst, H. M. (2004) G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 18, 1078-1084.
193. van Horssen, R., ten Hagen, T. L. M., Eggermont, A. M. M. (2006) TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397-408.
194. Wang, S., Wang, Z., Grant, S. (2003a) Bryostatin 1 and UCN-01 potentiate 1-β-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Mol. Pharmacol. 63, 232-242.
195. Wang, S., Yang, D., Lippman, M. E. (2003b) Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin. Oncol. 30, 133-142.
196. Wang, Z., Cuddy, M., Samuel, T., Welsh, K., Schimmer, A., Hanaii, F., Houghten, R., Pinilla, C., Reed, J. C. (2004) Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors. J. Biol. Chem. 279, 48168-48176.
197. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., Cotter, F. E. (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 18, 1812-1823.
198. Weber, T., Dalen, H., Andera, L., Negre-Salvayre, A., Auge, N., Sticha, M., Lloret, A., Terman, A., Witting, P. K., Higuchi, M., Plasilova, M., Zivny, J., Gellert, N., Weber, C., Neuzil, J. (2003) Mitochondria play a central role in apoptosis induced by α-tocopheryl succinate, an agent with antineoplastic activity: comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 42, 4277-4291.
199. Weisberg, E., Boulton, C., Kelly, L. M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D. G., Griffin, J. D. (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC4 12. Cancer Cell 1, 433-443.
200. Whittaker, S. R., Walton, M. I., Garrett, M. D., Workman, P. (2004) The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res. 64, 262-272.
201. Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., Dakhil, S. R., Gross, H., Kaufmann, S. H. (2005) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 23, 5347-5356.
202. Xu, X., Persson, H. L., Richardson, D. R. (2005) Molecular pharmacology of the interaction of anthracyclines with iron. Mol. Pharmacol. 68, 261-271.
203. Yamauchi, T., Keating, M. J., Plunkett, W. (2002) UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol. Cancer Ther. 1, 287-294.
204. Yanamandra, N., Colaco, N. M., Parquet, N. A., Buzzeo, R. W., Boulware, D., Wright, G., Perez, L. E., Dalton, W. S., Beaupre, D. M. (2006) Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res. 12, 591-599.
205. Yilmaz, O. H., Valdez, R., Theisen, B. K., Guo, W., Ferguson, D. O., Wu, H., Morrison, S. J. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482.
206. Yu, C., Rahmani, M., Conrad, D., Subler, M., Dent, P., Grant, S. (2003) The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to ST1571. Blood 102, 3765-3774.
207. Zangemeister-Wittke, U., Leech, S. H., Olie, R. A., Simoes-Wust, A. P., Gautschi, O., Luedke, G. H., Natt, F., Haner, R., Martin, P., Hall, J., Nalin, C. M., Stahel, R. A. (2000) A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 6, 2547-2555.
208. Zeytun, A., Nagarkatti, M., Nagarkatti, P. S. (2000) Growth of FasL-bearing tumor cells in syngeneic murine host induces apoptosis and toxicity in Fas(+) organs. Blood 95, 2111-2117.
209. Zhang, H. G., Wang, J., Yang, X., Hsu, H. C., Mountz, J. D. (2004) Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23, 2009-2015.